Novartis bid to sell new biosimilar crimped by U.S. court battles

ZURICH (Reuters) – Novartis has won U.S. approval for a copy of Amgen’s blockbuster arthritis drug Enbrel, but the Swiss drugmaker’s bid to muscle in on the medicine’s $4.7 billion in annual U.S. revenue remains blocked by court battles.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *